Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eloxatin, Alimta, and Bevacizumab in Advanced Non-Squamous NSCLC
NCT00251524Phase 2Completed
- Sponsor
- Veeda Lifesciences
- Start
- Nov 2005
- Primary completion
- May 2009
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, pemetrexed and bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Veeda Lifesciences. Primary endpoint: Progression-Free Survival. Started Nov 2005; status: completed.
02
Drugs
oxaliplatinpemetrexedbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00251524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251524.